Soluble PD-L1 as an early marker of progressive disease on nivolumab

Soluble PD-L1 as an early marker of progressive disease on nivolumab

Background Soluble PD-L1 (sPD-L1) has been associated with worse prognosis in numerous solid tumors. We determined sPD-L1 levels before and during nivolumab treatment in two prospective clinical trials of metastatic clear cell renal cell carcinoma (RCC) and melanoma patients, and investigated its re...

Full description

Saved in:
Bibliographic Details
Main Authors: David F McDermott, Gordon J Freeman, Toni K Choueiri, Petra Ross-MacDonald, F Stephen Hodi, Megan Wind-Rotolo, Long Yuan, Kathleen M Mahoney, Linan Song, Eliseo Veras
Format: Article
Language:English
Published: BMJ Publishing Group 2022-02-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/2/e003527.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items